Newsletter Vol. 7 In wrapping up the year, AGT was proud to be featured as a State of Maryland “Success Story” for its growth in Maryland and achievements in the gene and cell therapy industry. Watch The Vid...
American Gene Technologies International Inc. (AGT)
A private biotechnology company developing cures and treatments
for Infectious diseases, cancers and monogenic disorders.
AGT, has a broad, robust lentiviral delivery platform evolved over ten years of advanced development. AGT has an extensive and growing patent portfolio surrounding its lentiviral platform innovations that accelerate the development of a wide variety of drug candidates. This platform allows AGT to pursue exciting clinical “cures” in large and orphan indications and complex diseases. AGT’s proprietary platform technologies provide reusable components that allow AGT and its internationally recognized collaborators to create new therapies in a fraction of the time of traditional drug development processes and other drug companies. AGT is expecting to begin clinical trials this year for an HIV cure based on a successful pre-IND meetings with the FDA.
AGT has built a rich product pipeline of genetic therapies for patients suffering from infectious disease, monogenic disorders, and cancer, using its lentiviral vector platform and patented methods.
Latest AGT Tweets
We're excited for tonight's @MDTechCouncil Industry Awards! Thank you MTC and our colleagues for recognizing @AmericanGene as a finalist for #LifeSciences Company of the Year and @JeffreyGalvin as #CEO of the Year. All nominees are winners.
#biotech #genetherapy #makeanimpact https://t.co/IrDkHkPDCO